Yeasts: the basis for new vaccines

Efficient cell-mediated immunity requires the activation of dendritic cells (DC). Currently there is a great deal of interest in vaccine strategies that employ DC immunostimulatory complexes. In May Nature Medicine Andrew Stubbs and colleagues from the University of Colorado Health Sciences Center, Denver suggest that genetically engineered yeasts may be capable of acting as an immunostimulatory complex.

Stubbs et al demonstrated that recombinant Saccharomyces cerevisiae engineered to express tumor or HIV-1 antigens are capable of eliciting cytotoxic T lymphocyte–mediated responses and protective immunity in mice. Interactions between yeast and DCs led to DC maturation, IL-12 production and the efficient priming of MHC class I- and class II-restricted, antigen-specific T-cell responses (Nat Med 2001, 7:625-629).

Yeast also exerted a strong adjuvant effect, augmenting DC presentation of the exogenous whole-protein antigen to MHC class I- and class II-restricted T cells. This suggests that recombinant yeast may be a good...